MiNK Therapeutics (INKT) Institutional Ownership → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free INKT Stock Alerts $0.88 +0.01 (+1.15%) (As of 09:41 AM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for MiNK Therapeutics (NASDAQ:INKT)CurrentInstitutional OwnershipPercentage2.87%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$818.08KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$143.80K Get INKT Insider Trade Alerts Want to know when executives and insiders are buying or selling MiNK Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INKT Institutional Buying and Selling by Quarter Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 MiNK Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/14/2023Oracle Investment Management Inc.36,898$41K0.0%-26.9%0.107% 8/14/2023Oracle Investment Management Inc.50,461$106K0.1%N/A0.146% 8/14/2023Deep Track Capital LP324,867$682K0.0%N/A0.941% 8/11/2023Artal Group S.A.228,216$479K0.0%-21.2%0.663% 7/27/2023Virtu Financial LLC14,232$30K0.0%N/A0.041% 2/10/2023StoneX Group Inc.17,821$47K0.0%N/A0.053% 11/4/2022First Republic Investment Management Inc.81,500$172K0.0%N/A0.243% 2/15/2022Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031% (Data available from 1/1/2016 forward) INKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INKT shares? During the previous two years, the following institutional investors and hedge funds held shares of MiNK Therapeutics shares: Deep Track Capital LP ($682K), Artal Group S.A. ($479K), First Republic Investment Management Inc. ($172K), StoneX Group Inc. ($47K), and Oracle Investment Management Inc. ($41K), Virtu Financial LLC ($30K).Learn more on INKT's institutional investors. What percentage of MiNK Therapeutics stock is owned by institutional investors? 2.87% of MiNK Therapeutics stock is owned by institutional investors. Learn more on INKT's institutional investor holdings. Which institutional investors have been buying MiNK Therapeutics stock? The following institutional investors have purchased MiNK Therapeutics stock in the last 24 months: Deep Track Capital LP ($324.87K), First Republic Investment Management Inc. ($81.50K), Oracle Investment Management Inc. ($50.46K), StoneX Group Inc. ($17.82K), and Virtu Financial LLC ($14.23K). How much institutional buying is happening at MiNK Therapeutics? Institutional investors have bought a total of 488,881 shares in the last 24 months. This purchase volume represents approximately $1.04M in transactions. Which MiNK Therapeutics major shareholders have been selling company stock? The following institutional investors have sold MiNK Therapeutics stock in the last 24 months: Artal Group S.A. ($61.37K), and Oracle Investment Management Inc. ($13.56K). How much institutional selling is happening at MiNK Therapeutics? Institutional investors have sold a total of 74,935 shares in the last 24 months. This volume of shares sold represents approximately $143.80K in transactions. Related Companies: Achilles Therapeutics Institutional Ownership Surrozen Institutional Ownership Windtree Therapeutics Institutional Ownership IN8bio Institutional Ownership Protara Therapeutics Institutional Ownership Pluri Institutional Ownership Cyclo Therapeutics Institutional Ownership Brainstorm Cell Therapeutics Institutional Ownership Estrella Immunopharma Institutional Ownership ZIVO Bioscience Institutional Ownership This page (NASDAQ:INKT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
